BPC-157 Heals Haloperidol-Induced Stomach Damage Through Dopamine Pathway Interaction

BPC-157 and omeprazole healed haloperidol-induced gastric lesions while atropine and lansoprazole did not, confirming BPC-157's healing involves the central dopamine system rather than just acid suppression.

Bilic, I et al.·Life sciences·2001·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00651Animal StudyPreliminary Evidence2001RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

BPC-157, omeprazole, and bromocriptine healed haloperidol-induced gastric lesions, while atropine, lansoprazole, and cimetidine failed, demonstrating the lesions are dopamine-mediated and BPC-157 acts through dopaminergic mechanisms.

Key Numbers

How They Did This

Animal study in rats. Haloperidol-induced gastric lesions treated with BPC-157, omeprazole, bromocriptine, atropine, lansoprazole, or cimetidine. Lesion healing assessed. Prostaglandin and dopamine pathway contributions dissected.

Why This Research Matters

The selective healing pattern provides the strongest evidence yet that BPC-157 works through dopamine system interaction, not just general cytoprotection or acid reduction.

The Bigger Picture

BPC-157's dopaminergic mechanism distinguishes it from all conventional gastroprotective drugs. This unique mechanism explains why it heals damage that acid-reducing drugs cannot.

What This Study Doesn't Tell Us

Animal study. The specific dopamine receptor subtypes involved were not determined. Omeprazole's healing may work through a non-acid mechanism in this model.

Questions This Raises

  • ?Which dopamine receptor subtype does BPC-157 interact with?
  • ?Could BPC-157 prevent GI side effects in all patients taking antipsychotics?
  • ?Is BPC-157's dopamine interaction direct or indirect?

Trust & Context

Key Stat:
Dopamine, not acid BPC-157 healed haloperidol lesions that acid-blocking drugs couldn't touch — confirming its mechanism is dopaminergic, not acid-related
Evidence Grade:
Preliminary animal evidence with clear selective healing pattern providing mechanistic insight through comparative drug testing.
Study Age:
Published in 2001. BPC-157's dopamine system interaction has been further characterized in subsequent studies.
Original Title:
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
Published In:
Life sciences, 68(16), 1905-12 (2001)
Database ID:
RPEP-00651

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why can't regular stomach drugs heal these ulcers?

Haloperidol causes stomach damage through the dopamine system, not excess acid. Acid-blocking drugs like lansoprazole and cimetidine address the wrong mechanism. BPC-157 heals them because it works through the dopamine system.

Is this relevant for people on antipsychotics?

Potentially very relevant. Antipsychotic drugs work by blocking dopamine and commonly cause GI problems. BPC-157's ability to heal dopamine-related gut damage suggests it could protect patients' stomachs during antipsychotic therapy.

Read More on RethinkPeptides

Cite This Study

RPEP-00651·https://rethinkpeptides.com/research/RPEP-00651

APA

Bilic, I; Zoricic, I; Anic, T; Separovic, J; Stancic-Rokotov, D; Mikus, D; Buljat, G; Ivankovic, D; Aralica, G; Prkacin, I; Perovic, D; Mise, S; Rotkvic, I; Petek, M; Rucman, R; Seiwerth, S; Sikiric, P. (2001). Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.. Life sciences, 68(16), 1905-12.

MLA

Bilic, I, et al. "Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.." Life sciences, 2001.

RethinkPeptides

RethinkPeptides Research Database. "Haloperidol-stomach lesions attenuation by pentadecapeptide ..." RPEP-00651. Retrieved from https://rethinkpeptides.com/research/bilic-2001-haloperidolstomach-lesions-attenuation-by

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.